SCHEMBL21131047

SCHEMBL21131047

O=C(NCc1ccc(C(F)(F)F)cc1)N1CCOCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 1/20 0.58
▸ NOS1 P29475 1/20 0.58
▸ KMT2A Q03164 4/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ AKR1C3 P42330 1/20 0.53
▸ EPHX2 P34913 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ EPAS1 Q99814 1/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ HRH3 Q9Y5N1 1/20 0.51
▸ MTTP P55157 1/20 0.51
▸ HDAC1 Q13547 1/20 0.50
▸ HDAC2 Q92769 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ CASP1 P29466 2/20 0.49
▸ CASP7 P55210 2/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5740992 0.86 HRH3 (0.59) KMT2AMEN1KCNH2HRH3MTTP
SCHEMBL5464853 0.83 MEN1 (0.70) KMT2AMEN1EPHX2KCNH2HRH3
SCHEMBL32660728 0.83 KCNH2 (0.51) KMT2AMEN1KCNH2HRH3HDAC1
SCHEMBL1316827 0.81 NAMPT (0.62) NOS3NOS1KMT2AMEN1SMN1; SMN2
SCHEMBL8393626 0.81 USP2 (0.64) NOS3NOS1KMT2AMEN1HRH3
SCHEMBL20236868 0.80 NOS3 (0.61) NOS3NOS1KMT2AMEN1SMN1; SMN2
SCHEMBL28363944 0.78 SMN1; SMN2 (0.70) KMT2AMEN1SMN1; SMN2AKR1C3EPHX2
SCHEMBL18787412 0.78 ME2 (0.65) KMT2AMEN1SMN1; SMN2AKR1C3EPHX2
SCHEMBL5146518 0.78 NOS3 (0.59) NOS3NOS1KMT2AMEN1SMN1; SMN2
SCHEMBL4418944 0.78 CD274 (0.50) SMN1; SMN2AKR1C3EPHX2HIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190185462-A1 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185462-A1 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS HDAC6, HDAC1, HDAC5 NOS3 3391/4885NOS1 4131/4885KMT2A 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback